These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 32569853)

  • 1. Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis.
    Lau A; Yang WF; Li KY; Su YX
    Crit Rev Oncol Hematol; 2020 Sep; 153():102984. PubMed ID: 32569853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
    Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
    Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early recurrence, time-to-recurrence, and recurrence patterns: Assessing their impact on survival outcomes in head and neck squamous cell carcinoma (R/M-HNSCC) patients treated with first line platinum-based chemotherapy.
    Pitakpaiboonkul P; Jiarpinitnun C; Pattaranutaporn P; Ngamphaiboon N
    Cancer Med; 2024 Feb; 13(4):e7047. PubMed ID: 38457195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review.
    Lala M; Chirovsky D; Cheng JD; Mayawala K
    Oral Oncol; 2018 Sep; 84():108-120. PubMed ID: 30115469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma.
    Motai R; Sawabe M; Kadowaki S; Sasaki E; Nishikawa D; Suzuki H; Beppu S; Terada H; Hanai N
    Int J Clin Oncol; 2021 Jul; 26(7):1188-1195. PubMed ID: 33821363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of first-line systemic treatment regimens for recurrent/metastatic head and neck squamous cell carcinoma: a network meta-analysis.
    Yu X; Su X; Fang L; Zhang H; Chen X; Pu Y; Liu H; Guo R
    Eur Arch Otorhinolaryngol; 2023 Mar; 280(3):1391-1401. PubMed ID: 36181527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
    Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
    Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
    Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
    Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
    Lien MY; Wang TH; Hsieh CY; Tsai MH; Hua CH; Cheng FM; Chung WH; Tang CH; Chia-Hsun Hsieh J
    Oral Oncol; 2021 Aug; 119():105380. PubMed ID: 34146822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of anti-EGFR agents administered concurrently with standard therapies for patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis of randomized controlled trials.
    Tian Y; Lin J; Tian Y; Zhang G; Zeng X; Zheng R; Zhang W; Yuan Y
    Int J Cancer; 2018 Jun; 142(11):2198-2206. PubMed ID: 29143328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
    Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS
    Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
    Nadler E; Joo S; Boyd M; Black-Shinn J; Chirovsky D
    Future Oncol; 2019 Mar; 15(7):739-751. PubMed ID: 30511880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence.
    Ham JC; van Meerten E; Fiets WE; Beerepoot LV; Jeurissen FJF; Slingerland M; Jonker MA; Husson O; van der Graaf WTA; van Herpen CML
    Head Neck; 2020 May; 42(5):828-838. PubMed ID: 31903657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma.
    Specenier P; Vermorken JB
    Expert Rev Anticancer Ther; 2018 Sep; 18(9):901-915. PubMed ID: 29999437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.
    Grünwald V; Chirovsky D; Cheung WY; Bertolini F; Ahn MJ; Yang MH; Castro G; Berrocal A; Sjoquist K; Kuyas H; Auclair V; Guillaume X; Joo S; Shah R; Harrington K;
    Oral Oncol; 2020 Mar; 102():104526. PubMed ID: 31978755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with immune checkpoint inhibitors in recurrent or metastatic squamous cell carcinoma of the head and neck: A meta-analysis.
    Chen L; Mo DC; Hu M; He W; Yang QW; Tang J
    Int Immunopharmacol; 2023 Jun; 119():110270. PubMed ID: 37150013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Taguchi J; Shimizu Y; Ariga S; Goda T; Ohhara Y; Honma R; Noguchi T; Takeuchi S; Kinoshita I; Amano T; Mizumachi T; Kano S; Takahara M; Abe T; Homma A; Dosaka-Akita H
    Int J Clin Oncol; 2021 Jan; 26(1):51-58. PubMed ID: 32996023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.
    Sato H; Tsukahara K; Okamoto I; Katsube Y; Shimizu A; Kondo T; Hanyu K; Fushimi C; Okada T; Miura K
    Acta Otolaryngol; 2019 Feb; 139(2):201-205. PubMed ID: 30794080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.